例如:"lncRNA", "apoptosis", "WRKY"

Cysteinyl Leukotriene Receptor Antagonists Decrease Cancer Risk in Asthma Patients.

Sci Rep. 2016 Apr 07;6:23979
Ming-Ju Tsai 1 , Ping-Hsun Wu 2 , Chau-Chyun Sheu 3 , Ya-Ling Hsu 1 , Wei-An Chang 4 , Jen-Yu Hung 3 , Chih-Jen Yang 5 , Yi-Hsin Yang 6 , Po-Lin Kuo 2 , Ming-Shyan Huang 7
Ming-Ju Tsai 1 , Ping-Hsun Wu 2 , Chau-Chyun Sheu 3 , Ya-Ling Hsu 1 , Wei-An Chang 4 , Jen-Yu Hung 3 , Chih-Jen Yang 5 , Yi-Hsin Yang 6 , Po-Lin Kuo 2 , Ming-Shyan Huang 7
+ et al

[No authors listed]

Author information
  • 1 Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 2 Institute of Clinical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 3 Department of Internal Medicine, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 4 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 5 Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 6 School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • 7 Division of Geriatrics and Gerontology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

摘要


Previous in vitro and in vivo studies have demonstrated the potential of using cysteinyl leukotriene receptor antagonists (LTRAs) for chemoprevention, but this has not been investigated in any clinical setting. We therefore investigated the chemopreventive effect of LTRAs in a nationwide population-based study. From the Taiwan National Health Insurance Research Database, we enrolled adults with newly-diagnosed asthma between 2001 and 2011. Among these patients, each LTRA user was matched with five randomly-selected LTRA non-users by sex, age, asthma diagnostic year and modified Charlson Comorbidity Index score. We considered the development of cancer as the outcome. Totally, 4185 LTRA users and 20925 LTRA non-users were identified. LTRA users had a significantly lower cancer incidence rate than LTRA non-users did. Multivariable Cox regression analyses adjusting for baseline characteristics and comorbidities showed LTRA use was an independent protecting factor (hazard ratio = 0.31 [95% CI: 0.24-0.39]), and cancer risk decreased progressively with higher cumulative dose of LTRAs. In conclusion, this study revealed that the LTRA use decreased cancer risk in a dose-dependent manner in asthma patients. The chemopreventive effect of LTRAs deserves further study.

图表